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Abstract
Background: Prostate-specific membrane antigen (PSMA) is a well characterized prostate-specific
tumor associated antigen. Its expression is elevated in prostate carcinoma, particularly in metastatic
and recurrent lesions. These observations suggest that PSMA can be used as immune target to
induce tumor cell-specific recognition by the host and, consequently tumor rejection. We utilized
a DNA-based vaccine to specifically enhance PSMA expression. An immune modulator, such as
CpG oligodeoxynucleotides which promote Th1-type immune responses was combined to
increase the efficacy of tumor recognition and elimination.
Methods: A eukaryotic expression plasmid pCDNA3.1-PSMA encoding full-length PSMA was
constructed. C57BL/6 mice were immunized with endotoxin-free pCDNA3.1-PSMA alone or in
combination with CpG oligodeoxynucleotides by intramuscular injection. After 4 immunizations,
PSMA specific antibodies and cytotoxic T lymphocyte reactivity were measured. Immunized
C57BL/6 mice were also challenged subcutaneously with B16 cells transfected with PSMA to
evaluate suppression of tumor growth.
Results: Vaccine-specific cytotoxic T lymphocytes reactive with B16 cells expressing PSMA could
be induced with this treatment schedule. Immune protection was observed in vaccinated mice as
indicated by increased tumor growth in the control group (100%) compared with the groups
vaccinated with DNA alone (66.7%) or DNA plus CpG oligodeoxynucleotides (50%) respectively.
Average tumor volume was smaller in vaccinated groups and tumor-free survival time was
prolonged by the vaccination.
Conclusion:  The current findings suggest that specific anti-tumor immune response can be
induced by DNA vaccines expressing PSMA. In addition, the suppression of in vivo growth of tumor
cells expressing PSMA was augmented by CpG oligodeoxynucleotides. This strategy may provide
a new venue for the treatment of carcinoma of prostate after failure of standard therapy.
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Background
Carcinoma of prostate is the most common cancer in
males in America, ranking as the second most common
leading cause of cancer-related deaths, just after carci-
noma of the lung. In addition, the incidence and mortal-
ity of carcinoma of prostate are increasing in China.
Although surgery and radiation therapy remain the pri-
mary choice for localized stage of carcinoma of prostate,
there is no effective treatment for patients who develop
recurrences or those who have metastatic disease at the
time of diagnosis. Therefore, there is an urgent need for
new types of treatment.
Strategies that stimulate the ability of the immune system
to recognize and destroy cancer cells via selective killing
mechanisms have shown promise in the treatment of can-
cer. DNA vaccines offer several potential advantages for
the immunotherapy of cancer. Proteins encoded by DNA
vaccines are expressed in the cytoplasm and presented
through the endogenous processing pathway associated
with MHC Class I molecules, thereafter leading to the acti-
vation of CD8 + cytotoxic T lymphocytes (CTL) [1,2],
which act as effectors in the anti-tumor immune response.
DNA vaccines are cost-effective since DNA is relatively
simple to purify in a large quantities. Another intrinsic
advantage consists in the presence in the plasmid itself of
un-methylated CpG motifs (immunostimulatory
sequences) that may act as a potent immunological adju-
vant [3]. Thus, there is a good rationale for further devel-
opment of DNA vaccines to immunize against antigens
present on cancer cells.
Prostate specific membrane antigen (PSMA), a well-estab-
lished prostate specific tumor associated antigen (TAA), is
100 kD type II transmembrane glucoprotein. It is predom-
inantly expressed in the prostate gland, minimal levels of
expression in brain tissue, jejunum and proximal kidney
tubules [4,5]. Its expression is significantly elevated in car-
cinoma of prostate, particularly in metastastic disease and
recurrent disease after hormone therapy fails [6,7]. These
properties of PSMA propose it as an ideal target of anti-
cancer vaccines.
A number of strategies are under evaluation to enhance
the potency of DNA vaccines, some of which involves
broad stimulation of the immune system using immu-
nomodulatory agents. Synthetic CpG oligodeoxynucle-
otides have immunological effects similar to those seen
with bacterial DNA and represent promising vaccine adju-
vants, which promote T helper1 (Th1)-type immune
responses [8]. Unmethylated CpG motifs are present at a
much higher frequency in the genome of prokaryotes than
eukaryotes. The release of unmethylated CpG DNA during
an infection provides a 'danger signal' to the innate
immune system, triggering a protective immune response
that improves the ability of the host to eliminate the path-
ogen [9]. CpG oligodeoxynucleotides up-taken by B cells
and plasmacytoid dentritic cells (pDCs), which express
Toll-like receptror 9 (TLR9) [10,11] initiate an immune
stimulatory cascade that culminates in the indirect matu-
ration, differentiation and proliferation of T cells and nat-
ural killer (NK) cells[12,13]. Together, these cells secrete
cytokines and chemokines that create a pro-inflammatory
(IL-1, IL-6, IL-18 and tumor necrosis factor-α) and Th1-
polarized (interferon-γ, and IL-12) immune milieu [14],
which further facilitates the development of antigen-spe-
cific CTLs [15-17]. These effects indicate that CpG oligo-
deoxynucleotides could act as vaccine adjuvant. The
present study was designed to test the therapeutic efficacy
of a PSMA-based DNA vaccine in a mouse model of tumor
cell implants expressing PSMA. In addition, the adjuvant
role of CpG oligodeoxynucleotides to augment the
potency of the constructed DNA vaccine was tested.
Methods
Mice and Cell lines
C57BL/6 mice (H-2b) were bred and kept under patho-
gen-free conditions. Male mice were used at 12 to 16
weeks of age. All animal experiments were performed in
an approved protocol and in accordance with recommen-
dations for the proper care and use of laboratory animals.
The murine melanoma B16 cell was purchased from the
Type Culture Collection of the Chinese Academy of Sci-
ences and cultured in RPMI-1640 medium (Life Technol-
ogies, Gaithersburg, MD) supplemented with 10% (v/v)
heat-inactivated fetal bovine serum (Hyclone, Logan, UT),
penicillin G (100 U/ml), and streptomycin (100 µg/ml).
The COS-7 cell line was cultured in DMEM medium (Life
Technologies) supplemented with 10% (v/v) heat-inacti-
vated fetal bovine serum, sodium pyruvate (1 mM), peni-
cillin (100 U/ml) and streptomycin (100 µg/ml).
Antibodies and reagents
The monoclonal antibody 4A12 specific for an extra-cellu-
lar epitope of PSMA was previously described [18]. The β-
actin-specific monoclonal antibody was purchased from
Sigma Chemical Co (St. Louis, MO). FITC-labeled goat
anti-mouse IgG was purchased from Santa Cruz Biotech
(Santa Cruz, CA). Recombinant murine IL-2 was pur-
chased from PeproTech (Rocky Hill, NJ). ConA and mito-
mycin C were purchased from Sigma Chemical Co.
CpG oligodeoxynucleotides 1826 chosen according to
published data [19-21] had the following sequence
TTCATGACGTTCCTGACGTT (CpG motifs were shown
underlined) with the backbone phosphorothioate stabi-
lized. CpG oligodeoxynucleotides were synthesized by
Sangon (Shanghai, China), reconstituted in sterileJournal of Translational Medicine 2004, 2:29 http://www.translational-medicine.com/content/2/1/29
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pyrogen-free water and diluted in phosphate buffered
saline for in vivo injections.
Transient transfection of COS7 cells
The eukaryotic expression plasmid pCDNA3.1-PSMA
encoding full-length PSMA was constructed by cloning
the BamH I /Xho I fragment of pBluescipt-PSMA  as
described previously [18] into the pCDNA3.1 vector (Inv-
itrogen Corp, Carlsbad, CA) cut with identical
endonuclease.
COS-7 cells were transfected with pCDNA3.1-PSMA or an
empty (mock) vector by the mediation of liposome Tfx-
20™ (Promega, Madison, WI) according to the manufac-
turer's instructions. Briefly, COS-7 cells were cultured in
six-well tissue culture plates with a coverslip in each well
and grown to 50–70% confluence. 1.5 µg plasmid DNA
was mixed with 4.5 µl Tfx-20™ and diluted in 1000 µl
serum-free DMEM medium before addition to cells. After
20 minutes of incubation, DNA-liposome complex was
added to the cells and incubated for 6 hours at 5% CO2,
37°C. Complete DMEM medium containing 10% fetal
bovine serum was added to the cells and incubated over-
night, and then the medium was replaced with complete
DMEM medium. After 2 days, the cells were fixed in cold
acetone for 10 minutes at 4°C followed by extensive
washing with phosphate buffered saline. The cells were
incubated with anti-PSMA monoclonal antibody 4A12 for
1 hour at 37°C, subsequently incubated with FITC-
labeled goat anti-mouse IgG (1:40) for 1 hour at 37°C.
After thorough washing, the coverslips were mounted and
observed with a fluorescence microscope.
Stable transfection of B16 melanoma cells with PSMA 
plasmid
The B16 murine melanoma cells were transfected with 2
µg of pCDNA3.1-PSMA or empty vector by the mediation
of 6 µl liposome Tfx-20™ as above. After 2 days of culture,
the cells were reseeded into a 10 cm-dish and cultured for
other 2 days, complete RPMI-1640 medium containing
1000 µg/ml G418 (Life Technologies) was added to the
culture. After 20 days of selection, all non-transfected cells
died and discrete clones were visible in transfected cells.
These clones were expanded in the presence of 400 µg/ml
G418, positive cells expressing PSMA were identified as
follows.
Detection of PSMA mRNA by Reverse Transcriptase-PCR
Total RNA was extracted from mock-transfected or trans-
fected B16 cells using Trizol (Life Technologies) and dis-
solved in RNase free water. 2 µg of total RNA was
transcribed into cDNA using AMV reverse transcriptase
(Promega). Briefly, the total RNA was mixed with 1 µl
oligo (dT) primers (0.1 µg/ µl), 4 µl RT Buffer (5×), 2 µl
dNTPs (10 mM), 1 µl AMV reverse transcriptase and
diethypyrocarbonate-treated water to a final volume of 20
µl. The cDNA synthesis was performed using the follow-
ing PCR parameters: 37°C for 1 hour then 10 minutes at
95°C. Synthesized cDNA was used as template for PCR.
The sequence of the primers used were 5'- CGAGGAGGG
ATGGTG TT-3' (forward) and 5'-TGTTGTGGCTGCTT-
GAG-3' (reverse). PCR was carried out in a 10 µl aliquot
containing 0.5 µl cDNA, 0.5 µl each primer (10 µM), 1 µl
dNTPs (2 mM), 1 µl Taq buffer (10×), 0.8 µl MgCl2 (25
mM), 1 unit of Taq. The PCR reaction conditions included
5 minutes of initial denaturation at 94°C followed by 30
cycles of 30 seconds at 94°C, 1 minute at 62°C, 1 minute
at 72°C and 10 minutes of final extension at 72°C. The
358 bp fragment was resolved on 2% agarose gel. GAPDH
was also detected as internal reference.
Detection of PSMA protein by Western Blot
The transfected and mock-transfected B16 cells were har-
vested and lysed with lysis buffer (50 mM NaCl, 0.01 M
Tris-Cl (pH8.0), 5 mM EDTA, 0.5% NP-40, 1 mM phenyl-
methylsulfonyl fluoride, 1 µg/mL aprotinin, 1 µg/mL leu-
peptin) for 30 min at 4°C, cell debris were removed by
centrifugation. Cell lysates were heated at 100°C for 3
minutes, the samples were loaded on 6% SDS-PAGE for
electrophoresis. After electrophoresis, the proteins were
transferred to polyvinylidene difluoride membranes
(Amersham Pharmacia Biotech, Piscataway, NJ) using
semi-humid transferring system (Bio-Rad, Hercules, CA).
The polyvinylidene difluoride membranes were blocked
with Tris-buffered solution containing 5% (w/v) non-fat
milk for 1 hour at room temperature. For detection of pro-
tein, the polyvinylidene difluoride membranes were
probed with anti-PSMA monoclonal antibody 4A12 and
monoclonal antibody to β-actin (1:50) respectively for 1
hour at room temperature then overnight at 4°C, after
then the membranes were incubated with horse anti-
mouse IgG-HRP conjugate (1:500, Vector, Burlingame,
CA) for 1 hour at 37°C, ABC complex (1:500, Vector) for
1 hour at 37°C subsequently. The bands were visualized
with 3,3'-diaminobenzidine substrate solution (5 mg
diaminobenzidine dissolved in 10 ml Tris-buffered solu-
tion, 10 µl 30% hydrogen peroxide).
DNA vaccination of C57BL/6 mice
Plasmids pCDNA3.1-PSMA and pCDNA3.1 were purified
with EndoFree plasmid Maxi Kit (Qiagen, Valencia, CA).
Three groups including 6 mice each were immunized:
DNA vaccination group, CpG oligodeoxynucleotides and
DNA vaccine co-administration group (hereafter referred
to as CpG+DNA vaccination) and control group receiving
empty plasmid. All mice were injected with 0.25% lido-
caine in the quadriceps femoris muscle 3 days before vac-
cination in order to improve the uptaking of plasmids by
muscles. The mice then received bilateral intramuscular
injection with 50 µg of plasmid in the regeneratingJournal of Translational Medicine 2004, 2:29 http://www.translational-medicine.com/content/2/1/29
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muscles. Mice in the DNA vaccination group were immu-
nized with endotoxin-free pCDNA3.1-PSMA, mice in
CpG+DNA vaccination group were further immunized
with 25 µg of CpG oligodeoxynucleotides in the same
location 3 days after DNA plasmid immunization, as con-
trol, mice were injected with pCDNA3.1 plasmid. All mice
were boosted every 4 weeks for 3 times.
Measurement of PSMA specific serum antibodies
Two weeks after the last immunization, the mice were
bled and serum antibodies were measured by solid phase
enzyme-linked immunosorbent assay (ELISA). Briefly,
bacterially expressed fusion protein containing PSMA-
derived fragment was coated on 96-well plates. The plates
were blocked with 5% bovine serum albumin in phos-
phate buffered saline overnight at 4°C. The sera from
C57BL/6 mice were serially diluted in phosphate buffered
saline with 5% bovine serum albumin and then 100 µl of
diluted serum was added into each well. The plates were
incubated at 37°C for 1 hour, 100 µl of a 1:3000 dilution
of goat anti-mouse IgG-HRP conjugate (Jackson Immu-
noResearch, West Grove, PE) was added into each well
and incubated for 1 hour at 37°C, then 100 µl tetramethyl
benzidine (TMB) chromagen/substrate solution (0.1 mg/
ml TMB, 0.1 M citric acid buffer pH6.0, 4 µl 30% hydro-
gen peroxide per 10 ml) was added to each well. The
plates were read and the absorbance at 450 nm (A450)
was measured by microplate reader.
Cytotoxic T Lymphocyte (CTL) Assay
Two weeks after the last immunization, mice were sacri-
ficed. Their spleens were removed and teased apart in
serum-free RPMI-1640 media, the lymphocytes were col-
lected and cultured in RPMI-1640 medium supplemented
with 10% heat-inactivated fetal bovine serum, 50 IU/ml
recombinant murine IL-2 and 2 µg/ml ConA for 2 days.
B16 stimulator cells expressing PSMA (B16-PSMA) were
prepared in complete RPMI-1640 medium containing 50
µg/ml mitomycin C for 1 hour at 37°C. Two × 107 lym-
phocytes (responders) were incubated in 6-well plates
with 2 × 106 stimulator cells in the presence of 50 IU/ml
recombinant murine IL-2 and 2 µg/ml ConA. After 6 days
of culture, the re-stimulated cells were harvested and sep-
arated from the dead cells. Target cells (B16-PSMA) and
re-stimulated lymphocytes (effector cells) were resus-
pended in phenol red-free RPMI-1640 medium supple-
mented with 5% new born calf serum, 5 × 103 target cells
and various number of effector cells were added into indi-
vidual flat-bottom wells in 96-well plates. The cells were
incubated at 37°C overnight. 50 µl per well of superna-
tant was transferred to fresh 96-well plates. CTL reactivity
was assessed by measuring lactate dehydrogenase (LDH)
release using a Cytotox 96 assay kit (Promega). Controls
were setup on each plate for spontaneous LDH release by
target and effector cells. A parallel experiment using B16
cells transfected with pCDNA3.1 as target cells was also
performed to test the specificity of lysis. All experiments
were performed in triplicate. Percent lysis was calculated
according to manufacturer's instructions.
Subcutaneous transplantation of tumor cells
C57BL/6 mice were divided into 3 groups and immunized
as above. B16-PSMA cells were trypsinized and resus-
pended in phosphate buffered saline, 2 × 105 cells were
subcutaneously injected into the left lateral flank of mice.
The time to the development of tumor was recorded. After
tumors became detectable, their volume was measured
two-dimensionally with a caliper along the longest axis
(x) and the axis perpendicular to the longest axis (y) every
second days. The volume of tumors was estimated by the
following formula:
Volume = π/6 × x × y2
After 26 days, when tumor reached 20 mm in their largest
axis, the mice bearing tumors were sacrificed. Tumors
were removed and weighed.
Data Analysis
The data from ELISA and CTL assays are expressed as
means ± SD and are representative of at least three differ-
ent experiments. Comparisons between individual data
points were made using ANOVA or student's t-test. In the
tumor challenge experiment, the primary endpoint was
time of tumor appearance. Tumor-free survival time was
compared by the Kaplan-Meier method and log-rank sta-
tistic. P < 0.05 were considered significant.
Results
Expression of plasmid pCDNA3.1-PSMA in COS7 cells
To confirm the expression of PSMA in mammalian cells,
plasmid pCDNA3.1-PSMA  was introduced into COS7
cells. The cells were the incubated with anti-PSMA mono-
clonal antibody and goat anti-mouse IgG-FITC conjugate.
The immunofluorescence assay demonstrated that the
reactivity was present in the cytoplasm of COS7 cells
transfected with pCDNA3.1-PSMA but not in mock-trans-
fected cells, thus indicating that pCDNA3.1-PSMA could
express protein in mammalian cells (Figure 1). We consid-
ered that plasmid pCDNA3.1 containing the Simian virus
40 (SV40) origin of replication were rapidly amplified in
COS7 cells, which constitutively express SV40 large T anti-
gen (T-Ag), so pCDNA3.1-PSMA  underwent multiple
rounds of duplication within one cell generation. A large
amount of protein therefore was expressed and could not
be delivered completely through the transporting machin-
ery to cytomembrane, this may explain why the reactivity
was found in cytoplasm.Journal of Translational Medicine 2004, 2:29 http://www.translational-medicine.com/content/2/1/29
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Detection of PSMA mRNA
The transfected and mock-transfected B16 murine
melanoma cells were selected by G418 and, after 3 weeks
of selection, clones resistant to G418 were obtained. Total
RNA was extracted and reverse-transcribed into cDNA to
be used as template for PCR detection of PSMA mRNA. A
358 bp band was present in 3 B16 clones transfected with
pCDNA3.1-PSMA  but not in clones transfected with
pcDNA3.1 (Figure 2). GAPDH were detected in all sam-
ples (data not shown).
Detection of PSMA protein
The lysates from 3 clones with detectable PSMA mRNA
were resolved by 6% SDS-PAGE followed by immunob-
lotting. A predicted 100 kD band was identified in the 3
clones but not in mock-transfected B16 cells (Figure 3).
One of the clones was designated as B16-PSMA and used
as target cells for cytotoxic T lymphocytes (CTL) assay or
in tumor challenge experiment. A B16 cell line transfected
with pCDNA3.1 (referred to as B16-pCDNA) was also
obtained and used as negative control in CTL analysis.
Measurement of PSMA specific serum antibodies
ELISA was used to measure PSMA specific serum antibod-
ies in C57BL/6 mice. All mice immunized with
pCDNA3.1-PSMA  generated low titers of antibodies,
while PSMA specific antibodies were not detected in con-
trol group. When sera were diluted at 1:10,
1:20,1:40,1:80,1:160, the differences between control
group and other two groups were all statistically signifi-
cant (P < 0.001). However, titers were similar between the
DNA vaccine and the CpG+DNA vaccination groups (P >
0.05), suggesting that CpG oligodeoxynucleotides did not
augment the antigen-specific humoral immunity (Figure
4). The experiment was repeated 3 times with sera from
independently immunized mice yielding comparable
results.
Cytotoxic T Lymphocyte (CTL) Assay
Splenocytes from C57BL/6 mice were re-stimulated for 6
days with mitomycin C-treated B16-PSMA cells. Cytotox-
icity was measured by LDH release from attacked B16-
PSMA cells or B16-pCDNA cells. Splenocytes from mice in
Immunofluorescence staining of COS7 cells Figure 1
Immunofluorescence staining of COS7 cells. The COS7 cells were transfected with either pCDNA3.1-PSMA or empty 
pCDNA3.1 and fixed with cold aceton. Fixed cells were incubated with a anti-PSMA monoclonal antibody 4A12, stained with a 
goat anti-mouse immunoglobulin-FITC conjugate, PSMA immunoreactive cells were visualized with a fluorescent microscope 
(×40). Cytoplasmatic reactivity was found in COS7 cells transfected with pCDNA3.1-PSMA (A) but not in COS7 cells trans-
fected with pCDNA3.1 (B).Journal of Translational Medicine 2004, 2:29 http://www.translational-medicine.com/content/2/1/29
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the DNA vaccination group exhibited specific lysis against
B16-PSMA, whereas those from mice in the control group
did not acquire killing activity. The differences between
control group and the other two groups were statistically
significant at E:T ratios of 40:1, 20:1, 10:1 (P < 0.01).
More importantly, CTL reactivity was significantly
enhanced in mice treated with CpG oligodeoxynucle-
otides compared with DNA vaccine alone at E:T ratios of
40:1, 20:1 (t = 9.737, P < 0.001; t = 2.14,P = 0.021 respec-
tively) (Figure 5A). However, specific lysis was not
observed in all groups when B16-pCDNA cells were used
as target cells (Figure 5B).
Suppression of Tumor Growth in Tumor-bearing Mice by 
pCDNA3.1-PSMA
C57BL/6 mice (n= 6/group) were vaccinated with
pCDNA3.1-PSMA or empty vector, and then challenged
with B16-PSMA cells. Protection was observed in
pCDNA3.1-PSMA vaccinated mice with decrease of tumor
incidence. After 26 days, all mice in the control group
developed tumors while 2 (2/6) and 3 tumor-free mice
(3/6) were observed in the DNA and in the CpG + DNA
vaccination groups respectively. Kaplan-Meier curves
showed that the tumor-free survival interval was 19.67 ±
2.24 days in the DNA vaccination group, 22.33 ± 1.61
days in the CpG +DNA vaccination group and 13.17 ±
Detection of PSMA mRNA by RT-PCR Figure 2
Detection of PSMA mRNA by RT-PCR. The murine 
melanoma B16 cells were transfected with either 
pCDNA3.1-PSMA or empty pCDNA3.1 and selected by 
G418. After 20 days of selection, clones resistant to G418 
were acquired. Total RNA was extracted, and PSMA mRNA 
was detected by RT-PCR. 3 clones of B16 cells transfected 
with pCDNA3.1-PSMA were positive for PSMA mRNA, while 
B16 cells transfected with pCDNA3.1 were negative. Lanes 
1, 2 and 3, B16 clones transfected with pCDNA3.1-PSMA; 
lane 4, B16 clones transfected with pCDNA3.1.
Detection of PSMA protein by Western Blot Figure 3
Detection of PSMA protein by Western Blot. Total 
cell lysates were harvested and presence of PSMA protein 
was detected by anti-PSMA monoclonal antibody 4A12. A 
100 kD band was identified in 3 clones with detectable PSMA 
mRNA but not in B16 cells transfected with empty vector 
(A). Lane1, 2 and 3, B16 cells transfected with pCDNA3.1-
PSMA. Lane 4 B16 cells transfected with pCDNA3.1. β-actin 
was used as reference (B).
Measurement of PSMA specific serum antibodies Figure 4
Measurement of PSMA specific serum antibodies. 
Mice were immunized 4 times at 4 weeks intervals by intra-
muscular injection with pCDNA3.1-PSMA or pCDNA3.1, 
antibody titers were measured by ELISA. Sera were serially 
diluted and measured individually. The experiment was per-
formed in triplicate. Shown is the average antibody titer (n = 
6) with standard errors. P valure was calculated by ANOVA. 
Antibody titer was similar in DNA vaccination group and 
CpG + DNA vaccination group, no antibody was detected in 
control group. * indicated the difference between control 
group with other two groups was statistically significant (P < 
0.05).Journal of Translational Medicine 2004, 2:29 http://www.translational-medicine.com/content/2/1/29
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1.01 in the control group (Fig. 6A). The difference
between DNA vaccination group and control group was
statistically significant (P = 0.0161), so was the difference
between CpG+DNA vaccination group and control group
(P  = 0.0016). Tumor-free survival time was longer in
Cytotoxic T Lymphocyte (CTL) Assay Figure 5
Cytotoxic T Lymphocyte (CTL) Assay. Splenocytes 
from C57BL/6 mice were re-stimulated for 6 days with mito-
mycin C-treated B16-PSMA cells. Cytotoxicity was measured 
by LDH release assay. The experiment was carried out in 
triplicate. Shown is the average CTL (n = 6) with standard 
errors. When B16-PSMA cells were used as target cells, spe-
cific lysis was found in DNA vaccination group but not in 
control group. The CTL reaction was enhanced by CpG oli-
godeoxynucleotides(Fig. 5A). However, when the mock-
transfected B16-pCDNA cells were used as target cells, spe-
cific lysis was not observed in all groups (Fig. 5B). * indicated 
the difference between control group with other two groups 
was statistically significant (P < 0.05);  indicated the differ-
ence between DNA vaccination group and CpG + DNA vac-
cination group was statistically significant (P < 0.05).
Suppressive Effects of DNA vaccine to Tumor Growth Figure 6
Suppressive Effects of DNA vaccine to Tumor 
Growth. C57BL/6 mice (n= 6/group) were vaccinated with 
pCDNA3.1-PSMA or empty vector, and then challenged with 
B16-PSMA cells. Kaplan-Meier curves showed the tumor-free 
survival time of mice was 19.67 ± 2.24 days in DNA vaccine 
group, 22.33 ± 1.61 days in CpG + DNA and 13.17 ± 1.01 
days in control group respectively (Fig. 6A). Some mice still 
developed tumors after pCDNA3.1-PSMA and CpG oligode-
oxynucleotides vaccination, but the individual tumors grew 
much more slowly than those in control group (Fig. 6B). Two 
mice in control group died before the termination of the 
experiment, all mice bearing tumor were sacrificed and 
tumor tissues were removed, the volumes of tumors in con-
trol group were larger than those in other two groups (Fig. 
6C).
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CpG+DNA vaccination group than DNA vaccination
group, but the difference was of no statistical significance
(P = 0.49). This observation may be associated with the
small number in each group.
Although mice developed tumors after pCDNA3.1-PSMA
vaccination, the individual tumors were consistently
smaller than those in the control group and the analysis
of tumor growth kinetics indicated that the tumor growth
was significantly slower in the CpG +DNA vaccination
group compared to the other two groups (Fig. 6B).
The volume of the tumors in the control group was con-
sistently larger than in other two groups (Fig. 6C) and the
average tumor weight was 2.28 ± 0.51 g in the DNA vac-
cine group, 1.10 ± 0.70 g in CpG + DNA group and 4.75
± 0.66 g in the control group. The differences between
control group and DNA vaccination group, CpG +DNA
vaccination group were statistically significant (t = 5.92, P
= 0.001; t = 7.062, P = 0.001 respectively). Moreover, the
difference between DNA vaccination group and CpG
+DNA vaccination group was statistically significant (t =
2.588, P = 0.049).
Discussion
Although treatments are available for organ-confined car-
cinoma of prostate, there is no effective approach to treat
recurrent disease after androgen deprivation therapy fails.
New approaches are required to treat this incurable dis-
ease. DNA vaccination enables maintenance of tumor
antigen expression at the vaccination site and results in
immune responses in the host, therefore, shedding light
on the treatment of cancer. It has been reported that
tumor growth is suppressed when tumor cells are
implanted in mice previously immunized with DNA vac-
cines encoding tumor antigens [22-25].
PSMA is a well-defined prostate-restricted tumor associ-
ated antigen whose expression is significantly elevated in
carcinoma of prostate, especially in advanced stages. The
expression of PSMA is down-regulated by androgen, after
androgen deprivation therapy, its expression is strongly
elevated[6,26-28], Thus, PSMA is a potential target for the
immunotherapy to carcinoma of prostate. Several PSMA-
based vaccines had been developed and it has been
observed in a phase II trial utilizing MHC Class I-restricted
peptides that PSMA can induce immune responses in
patients with advanced carcinoma of prostate and
alleviate the disease [29-31]. This observation suggests
PSMA as an appropriate target of active-specific immuni-
zation against carcinoma of prostate. However, standard
methods of protein/epitope preparations often coupled to
the adoptive transfer of antigen presenting cells are labor-
intensive decreasing the widespread use of vaccines in the
general cancer patient population.
The purpose of our work was to delineate new ways to
induce immune responses by DNA vaccination. In this
study, all mice immunized with DNA vaccine expressing
PSMA generated PSMA specific antibodies at a low level,
which may result from the small amount of antigen
expressed by plasmid in vivo. What is noteworthy is that
all immunized mice developed CTL reactivity to B16-
PSMA which led to suppression of tumor growth. In addi-
tion, although some tumors developed in some treated
mice, they were consistently smaller in the control group.
These findings suggest that DNA vaccines expressing
PSMA could elicit immune response against tumor cells
expressing the target molecule.
Although DNA vaccines provide a convenient and effec-
tive approach to elicit cellular immunity, clinical out-
comes have not been satisfactory, mainly because tumor-
specific CTL elicited by the vaccines are insufficient to
suppress cancer progression. CD8+ CTLs constitute one of
the most important arms of the immune system, exhibit-
ing the capacity of recognizing and destroying cancerous
cells[32,33]. A variety of approaches are under evaluation
to activate CD8+ CTLs, to that end, vaccines need to be
administered in combination with adjuvants of which the
most commonly used in experimental models is incom-
plete Freud's adjuvant (IFA). However, this adjuvant is not
widely used in human vaccination protocols due to its
undesirable side effects, such as erythema and induration
at the injection site, in addition, IFA functions mainly to
promote humoral immunity. For these reasons, alterna-
tive potent and safe adjuvants need to be identified to
enhance cellular immune response against cancer [34,35].
Synthetic CpG oligodeoxynucleotides represent a promis-
ing adjuvant. The predominant effect of CpG
oligodeoxynucleotides exposure is the promotion of Th1-
type immune responses. Professional antigen presenting
uptake CpG oligodeoxynucleotides and become activated
with increased expression of MHC and co-stimulatory
molecules [36-38] that promote antigen presentation to
naïve T cells. In addition, dentritic cells are stimulated to
secret Th1-biased cytokines, such as interferon-γ and IL-12
particularly desirable in cancer immunotherapy [39,40].
Therefore, CpG oligodeoxynucleotides may be useful vac-
cine adjuvants.
CpG oligodeoxynucleotides 1826 is a potent enhancer of
Th1-type immune responses and may benefit anti-cancer
therapy [41-43]. We, therefore, hypothesized that the
administration of these CpG oligodeoxynucleotides
should enhance the cellular immunity elicited by DNA
vaccines. However, co-adminstration of CpG oligodeoxy-
nucleotides and DNA vaccines inhibit each other activity
because CpG oligodeoxynucleotides may compete with
plasmid uptake by antigen presenting cells. Furthermore,Journal of Translational Medicine 2004, 2:29 http://www.translational-medicine.com/content/2/1/29
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IFN-γinduced by CpG oligodeoxynucleotides could
inhibit the activity of the CMV promoter utilized by
eukaryotic expression vector, thus decreasing antigen
expression. To examine the efficacy of CpG oligodeoxynu-
cleotides as vaccine adjuvants, we injected them at the
DNA injection site 3 days after vaccination rather than
simultaneously. This strategy was based on a previous
observation that transfected cells reach maximum yield of
antigen expression between day 2 and 3 after vaccination.
In this context, delivering the CpG oligodeoxynucleotides
at the time of maximal antigen expression may be crucial
to optimize the immunogenic boost [44,45].
Consistent with previous reports, this study suggests that
CpG oligodeoxynucleotides enhance cellular immunity.
The activity of CTL against PSMA expressing cells in the
CpG +DNA vaccination group was significantly higher
than in the DNA vaccination group. Furthermore, tumor
challenge experiments demonstrated a potentiation of the
suppressive effects on the growth of tumor cells expressing
PSMA. These findings indicate that CpG oligodeoxynucle-
otides should be a powerful adjuvant in the context of
DNA-based vaccination.
Conclusions
In this study, we designed a DNA vaccine expressing pros-
tate specific membrane antigen (PSMA) and utilized CpG
oligodeoxynucleotides to promote Th1-type immune
response. We discovered that the constructed vaccine gen-
erated anti-tumor reactivity against malignant cells
expressing PSMA that was enhanced by CpG oligodeoxy-
nucleotides co-administration. This strategy may provide
a new venue for the treatment of carcinoma of prostate,
particularly for recurrent disease after hormone therapy
fails.
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